Trial Profile

A Phase 1 Study of Neoadjuvant Chemotherapy, Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib, and Vorinostat in Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Vorinostat (Primary) ; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

16 Sep 2022 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
18 May 2020 Planned number of patients changed from 36 to 23.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com